Cost-utility analysis of reslizumab for patients with severe eosinophilic asthma inadequately controlled with high-dose inhaled corticosteroids and long-acting β 2 -agonists in South Korea

Sola Han
Sola Han
Siin Kim
Siin Kim

Current medical research and opinion, 2019, Pages 1-1.

Cited by: 0|Bibtex|Views0|DOI:https://doi.org/10.1080/03007995.2019.1605159
WOS
Other Links: pubmed.ncbi.nlm.nih.gov|academic.microsoft.com

Abstract:

The addition of reslizumab to high-dose ICS/LABA was cost-effective in Korean patients with severe eosinophilic asthma uncontrolled with high-dose ICS/LABA, based on the threshold of 1 gross domestic product in Korea.

Code:

Data:

Your rating :
0

 

Tags
Comments